Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.

Ozempic and other similar drugs must be injected. Messer describes the needle as “small, the size of two human hairs.” ...

With Roche's latest deal, a new contender enters the obesity space, which could threaten NVO and LLY's dominance in the ...

Novo Nordisk says many Australians would be willing to pay the out-of-pocket costs for its blockbuster medicines, which can ...

CagriSema, which is a combination of cagrilintide 2.4-milligram and semaglutide 2.4-mg doses, is being developed so people have a better choice for a weight-loss drug when the patents on Ozempic and ...

Shares of Novo Nordisk A/S were getting hit hard Monday, after the maker of Ozempic and Wegovy, the diabetes and obesity treatments, revealed data showing that its new weight-loss drug candidate ...

Novo Nordisk stock slumps as the 15.7% weight loss achieved with its next-gen obesity candidate, CagriSema, in the second ...

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

Roche's treatment is also an injectable under study that contains GLP-1 receptor agonists, the same key ingredients used in Novo Nordisk’s Ozempic and Wegovy and Lilly's Mounjaro and Zepbound.